Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Drug Profile

Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Alternative Names: anti-C3 protease - Catalyst Biosciences; CB 2782; CB 2782-PEG

Latest Information Update: 02 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; Mosaic Biosciences
  • Class Anti-inflammatories; Eye disorder therapies; Peptide hydrolases
  • Mechanism of Action Complement C3 inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry age-related macular degeneration; Retinal disorders

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Retinal disorders
  • Discontinued Delayed graft function; Inflammation

Most Recent Events

  • 29 Apr 2019 Pharmacodynamics and pharmacokinetics data from preclinical studies in Dry age-related macular degeneration released by Catalyst Biosciences and Mosaic Biosciences
  • 31 Oct 2017 Catalyst Biosciences and Mosaic Biosciences enter into collaboration to develop intravitreal anti-complement component C3 proteases for the treatment of Dry-age related macular degeneration and Retinal disorders
  • 24 Oct 2017 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top